Cargando…

HO-1089 and HO-1197, Novel Herbal Formulas, Have Antitumor Effects via Suppression of PLK1 (Polo-like Kinase 1) Expression in Hepatocellular Carcinoma

SIMPLE SUMMARY: HO-1089 and HO-1197 have potential to be developed as herbal medicine or as part of combination therapy in HCC. Additionally, development of PLK1 inhibition as a therapeutic strategy for HCC will require more study into the selection of patients based upon molecular vulnerabilities a...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Yeonhwa, Lee, Su-Yeon, Kim, Sanghwa, Choi, Inhee, Kim, Namjeong, Park, Jongmin, Seo, Haeng Ran
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913440/
https://www.ncbi.nlm.nih.gov/pubmed/36765811
http://dx.doi.org/10.3390/cancers15030851
_version_ 1784885427992264704
author Song, Yeonhwa
Lee, Su-Yeon
Kim, Sanghwa
Choi, Inhee
Kim, Namjeong
Park, Jongmin
Seo, Haeng Ran
author_facet Song, Yeonhwa
Lee, Su-Yeon
Kim, Sanghwa
Choi, Inhee
Kim, Namjeong
Park, Jongmin
Seo, Haeng Ran
author_sort Song, Yeonhwa
collection PubMed
description SIMPLE SUMMARY: HO-1089 and HO-1197 have potential to be developed as herbal medicine or as part of combination therapy in HCC. Additionally, development of PLK1 inhibition as a therapeutic strategy for HCC will require more study into the selection of patients based upon molecular vulnerabilities and the development of mechanism-based, rationally-selected combination of herbs. ABSTRACT: The treatment for hepatocellular carcinoma (HCC), a severe cancer with a very high mortality rate, begins with the surgical resection of the primary tumor. For metastasis or for tumors that cannot be resected, sorafenib, a multi-tyrosine protein kinase inhibitor, is usually the drug of choice. However, typically, neither resection nor sorafenib provides a cure. The drug discovery strategy for HCC therapy is shifting from monotherapies to combination regimens that combine an immuno-oncology agent with an angiogenesis inhibitor. Herbal formulas can be included in the combinations used for this personalized medicine approach. In this study, we evaluated the HCC anticancer efficacy of the new herbal formula, HO-1089. Treatment with HO-1089 inhibited HCC tumor growth by inducing DNA damage-mediated apoptosis and by arresting HCC cell replication during the G2/M phase. HO-1089 also attenuated the migratory capacity of HCC cells via the inhibition of the expression of EMT-related proteins. Biological pathways involved in metabolism and the mitotic cell cycle were suppressed in HO-1089-treated HCC cells. HO-1089 attenuated expression of the G2/M phase regulatory protein, PLK1 (polo-like kinase 1), in HCC cells. HCC xenograft mouse models revealed that the daily oral administration of HO-1089 retarded tumor growth without systemic toxicity in vivo. The use of HO-1197, a novel herbal formula derived from HO-1089, resulted in statistically significant improved anticancer efficacy relative to HO-1089 in HCC. These results suggest that HO-1089 is a safe and potent integrated natural medicine for HCC therapy.
format Online
Article
Text
id pubmed-9913440
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99134402023-02-11 HO-1089 and HO-1197, Novel Herbal Formulas, Have Antitumor Effects via Suppression of PLK1 (Polo-like Kinase 1) Expression in Hepatocellular Carcinoma Song, Yeonhwa Lee, Su-Yeon Kim, Sanghwa Choi, Inhee Kim, Namjeong Park, Jongmin Seo, Haeng Ran Cancers (Basel) Article SIMPLE SUMMARY: HO-1089 and HO-1197 have potential to be developed as herbal medicine or as part of combination therapy in HCC. Additionally, development of PLK1 inhibition as a therapeutic strategy for HCC will require more study into the selection of patients based upon molecular vulnerabilities and the development of mechanism-based, rationally-selected combination of herbs. ABSTRACT: The treatment for hepatocellular carcinoma (HCC), a severe cancer with a very high mortality rate, begins with the surgical resection of the primary tumor. For metastasis or for tumors that cannot be resected, sorafenib, a multi-tyrosine protein kinase inhibitor, is usually the drug of choice. However, typically, neither resection nor sorafenib provides a cure. The drug discovery strategy for HCC therapy is shifting from monotherapies to combination regimens that combine an immuno-oncology agent with an angiogenesis inhibitor. Herbal formulas can be included in the combinations used for this personalized medicine approach. In this study, we evaluated the HCC anticancer efficacy of the new herbal formula, HO-1089. Treatment with HO-1089 inhibited HCC tumor growth by inducing DNA damage-mediated apoptosis and by arresting HCC cell replication during the G2/M phase. HO-1089 also attenuated the migratory capacity of HCC cells via the inhibition of the expression of EMT-related proteins. Biological pathways involved in metabolism and the mitotic cell cycle were suppressed in HO-1089-treated HCC cells. HO-1089 attenuated expression of the G2/M phase regulatory protein, PLK1 (polo-like kinase 1), in HCC cells. HCC xenograft mouse models revealed that the daily oral administration of HO-1089 retarded tumor growth without systemic toxicity in vivo. The use of HO-1197, a novel herbal formula derived from HO-1089, resulted in statistically significant improved anticancer efficacy relative to HO-1089 in HCC. These results suggest that HO-1089 is a safe and potent integrated natural medicine for HCC therapy. MDPI 2023-01-30 /pmc/articles/PMC9913440/ /pubmed/36765811 http://dx.doi.org/10.3390/cancers15030851 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Song, Yeonhwa
Lee, Su-Yeon
Kim, Sanghwa
Choi, Inhee
Kim, Namjeong
Park, Jongmin
Seo, Haeng Ran
HO-1089 and HO-1197, Novel Herbal Formulas, Have Antitumor Effects via Suppression of PLK1 (Polo-like Kinase 1) Expression in Hepatocellular Carcinoma
title HO-1089 and HO-1197, Novel Herbal Formulas, Have Antitumor Effects via Suppression of PLK1 (Polo-like Kinase 1) Expression in Hepatocellular Carcinoma
title_full HO-1089 and HO-1197, Novel Herbal Formulas, Have Antitumor Effects via Suppression of PLK1 (Polo-like Kinase 1) Expression in Hepatocellular Carcinoma
title_fullStr HO-1089 and HO-1197, Novel Herbal Formulas, Have Antitumor Effects via Suppression of PLK1 (Polo-like Kinase 1) Expression in Hepatocellular Carcinoma
title_full_unstemmed HO-1089 and HO-1197, Novel Herbal Formulas, Have Antitumor Effects via Suppression of PLK1 (Polo-like Kinase 1) Expression in Hepatocellular Carcinoma
title_short HO-1089 and HO-1197, Novel Herbal Formulas, Have Antitumor Effects via Suppression of PLK1 (Polo-like Kinase 1) Expression in Hepatocellular Carcinoma
title_sort ho-1089 and ho-1197, novel herbal formulas, have antitumor effects via suppression of plk1 (polo-like kinase 1) expression in hepatocellular carcinoma
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9913440/
https://www.ncbi.nlm.nih.gov/pubmed/36765811
http://dx.doi.org/10.3390/cancers15030851
work_keys_str_mv AT songyeonhwa ho1089andho1197novelherbalformulashaveantitumoreffectsviasuppressionofplk1pololikekinase1expressioninhepatocellularcarcinoma
AT leesuyeon ho1089andho1197novelherbalformulashaveantitumoreffectsviasuppressionofplk1pololikekinase1expressioninhepatocellularcarcinoma
AT kimsanghwa ho1089andho1197novelherbalformulashaveantitumoreffectsviasuppressionofplk1pololikekinase1expressioninhepatocellularcarcinoma
AT choiinhee ho1089andho1197novelherbalformulashaveantitumoreffectsviasuppressionofplk1pololikekinase1expressioninhepatocellularcarcinoma
AT kimnamjeong ho1089andho1197novelherbalformulashaveantitumoreffectsviasuppressionofplk1pololikekinase1expressioninhepatocellularcarcinoma
AT parkjongmin ho1089andho1197novelherbalformulashaveantitumoreffectsviasuppressionofplk1pololikekinase1expressioninhepatocellularcarcinoma
AT seohaengran ho1089andho1197novelherbalformulashaveantitumoreffectsviasuppressionofplk1pololikekinase1expressioninhepatocellularcarcinoma